Deborah S Hasin1,2,3, Aaron L Sarvet1,3, Jacquelyn L Meyers4, Tulshi D Saha5, W June Ruan5, Malka Stohl3, Bridget F Grant6. 1. Department of Psychiatry, Columbia University Medical Center, New York, New York. 2. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York. 3. New York State Psychiatric Institute, New York. 4. Department of Psychiatry, State University of New York Downstate Medical Center, Brooklyn. 5. Epidemiology and Biometry Branch, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland. 6. Fedpoint Systems, LLC, Arlington, Virginia.
Abstract
Importance: No US national data are available on the prevalence and correlates of DSM-5-defined major depressive disorder (MDD) or on MDD specifiers as defined in DSM-5. Objective: To present current nationally representative findings on the prevalence, correlates, psychiatric comorbidity, functioning, and treatment of DSM-5 MDD and initial information on the prevalence, severity, and treatment of DSM-5 MDD severity, anxious/distressed specifier, and mixed-features specifier, as well as cases that would have been characterized as bereavement in DSM-IV. Design, Setting, and Participants: In-person interviews with a representative sample of US noninstitutionalized civilian adults (≥18 years) (n = 36 309) who participated in the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III). Data were collected from April 2012 to June 2013 and were analyzed in 2016-2017. Main Outcomes and Measures: Prevalence of DSM-5 MDD and the DSM-5 specifiers. Odds ratios (ORs), adjusted ORs (aORs), and 95% CIs indicated associations with demographic characteristics and other psychiatric disorders. Results: Of the 36 309 adult participants in NESARC-III, 12-month and lifetime prevalences of MDD were 10.4% and 20.6%, respectively. Odds of 12-month MDD were significantly lower in men (OR, 0.5; 95% CI, 0.46-0.55) and in African American (OR, 0.6; 95% CI, 0.54-0.68), Asian/Pacific Islander (OR, 0.6; 95% CI, 0.45-0.67), and Hispanic (OR, 0.7; 95% CI, 0.62-0.78) adults than in white adults and were higher in younger adults (age range, 18-29 years; OR, 3.0; 95% CI, 2.48-3.55) and those with low incomes ($19 999 or less; OR, 1.7; 95% CI, 1.49-2.04). Associations of MDD with psychiatric disorders ranged from an aOR of 2.1 (95% CI, 1.84-2.35) for specific phobia to an aOR of 5.7 (95% CI, 4.98-6.50) for generalized anxiety disorder. Associations of MDD with substance use disorders ranged from an aOR of 1.8 (95% CI, 1.63-2.01) for alcohol to an aOR of 3.0 (95% CI, 2.57-3.55) for any drug. Most lifetime MDD cases were moderate (39.7%) or severe (49.5%). Almost 70% with lifetime MDD had some type of treatment. Functioning among those with severe MDD was approximately 1 SD below the national mean. Among 12.9% of those with lifetime MDD, all episodes occurred just after the death of someone close and lasted less than 2 months. The anxious/distressed specifier characterized 74.6% of MDD cases, and the mixed-features specifier characterized 15.5%. Controlling for severity, both specifiers were associated with early onset, poor course and functioning, and suicidality. Conclusions and Relevance: Among US adults, DSM-5 MDD is highly prevalent, comorbid, and disabling. While most cases received some treatment, a substantial minority did not. Much remains to be learned about the DSM-5 MDD specifiers in the general population.
Importance: No US national data are available on the prevalence and correlates of DSM-5-defined major depressive disorder (MDD) or on MDD specifiers as defined in DSM-5. Objective: To present current nationally representative findings on the prevalence, correlates, psychiatric comorbidity, functioning, and treatment of DSM-5 MDD and initial information on the prevalence, severity, and treatment of DSM-5 MDD severity, anxious/distressed specifier, and mixed-features specifier, as well as cases that would have been characterized as bereavement in DSM-IV. Design, Setting, and Participants: In-person interviews with a representative sample of US noninstitutionalized civilian adults (≥18 years) (n = 36 309) who participated in the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III). Data were collected from April 2012 to June 2013 and were analyzed in 2016-2017. Main Outcomes and Measures: Prevalence of DSM-5 MDD and the DSM-5 specifiers. Odds ratios (ORs), adjusted ORs (aORs), and 95% CIs indicated associations with demographic characteristics and other psychiatric disorders. Results: Of the 36 309 adult participants in NESARC-III, 12-month and lifetime prevalences of MDD were 10.4% and 20.6%, respectively. Odds of 12-month MDD were significantly lower in men (OR, 0.5; 95% CI, 0.46-0.55) and in African American (OR, 0.6; 95% CI, 0.54-0.68), Asian/Pacific Islander (OR, 0.6; 95% CI, 0.45-0.67), and Hispanic (OR, 0.7; 95% CI, 0.62-0.78) adults than in white adults and were higher in younger adults (age range, 18-29 years; OR, 3.0; 95% CI, 2.48-3.55) and those with low incomes ($19 999 or less; OR, 1.7; 95% CI, 1.49-2.04). Associations of MDD with psychiatric disorders ranged from an aOR of 2.1 (95% CI, 1.84-2.35) for specific phobia to an aOR of 5.7 (95% CI, 4.98-6.50) for generalized anxiety disorder. Associations of MDD with substance use disorders ranged from an aOR of 1.8 (95% CI, 1.63-2.01) for alcohol to an aOR of 3.0 (95% CI, 2.57-3.55) for any drug. Most lifetime MDD cases were moderate (39.7%) or severe (49.5%). Almost 70% with lifetime MDD had some type of treatment. Functioning among those with severe MDD was approximately 1 SD below the national mean. Among 12.9% of those with lifetime MDD, all episodes occurred just after the death of someone close and lasted less than 2 months. The anxious/distressed specifier characterized 74.6% of MDD cases, and the mixed-features specifier characterized 15.5%. Controlling for severity, both specifiers were associated with early onset, poor course and functioning, and suicidality. Conclusions and Relevance: Among US adults, DSM-5 MDD is highly prevalent, comorbid, and disabling. While most cases received some treatment, a substantial minority did not. Much remains to be learned about the DSM-5 MDD specifiers in the general population.
Authors: David S Fink; Ranran Hu; Magdalena Cerdá; Katherine M Keyes; Brandon D L Marshall; Sandro Galea; Silvia S Martins Journal: Drug Alcohol Depend Date: 2015-05-19 Impact factor: 4.492
Authors: Naomi M Simon; Katherine M Shear; Elizabeth H Thompson; Alyson K Zalta; Carol Perlman; Charles F Reynolds; Ellen Frank; Nadine M Melhem; Russell Silowash Journal: Compr Psychiatry Date: 2007-07-05 Impact factor: 3.735
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Bridget F Grant; Deborah A Dawson; Frederick S Stinson; Patricia S Chou; Ward Kay; Roger Pickering Journal: Drug Alcohol Depend Date: 2003-07-20 Impact factor: 4.492
Authors: Jeremy D Goldhaber-Fiebert; Lea Prince; Lan Xiao; Nan Lv; Lisa G Rosas; Elizabeth M Venditti; Megan A Lewis; Mark B Snowden; Jun Ma Journal: Obesity (Silver Spring) Date: 2020-04-22 Impact factor: 5.002
Authors: Lisa G Rosas; Kristen M J Azar; Nan Lv; Lan Xiao; Jeremy D Goldhaber-Fiebert; Mark B Snowden; Elizabeth M Venditti; Megan M Lewis; Andrea N Goldstein-Piekarski; Jun Ma Journal: Am J Prev Med Date: 2020-02-14 Impact factor: 5.043
Authors: Jonathan Ross; Simin Hua; Krista M Perreira; David B Hanna; Sheila F Castañeda; Linda C Gallo; Frank J Penedo; Wassim Tarraf; Rosalba Hernandez; Natan Vega Potler; Gregory A Talavera; Martha L Daviglus; Franklyn Gonzalez; Robert C Kaplan; Sylvia Smoller-Wassertheil Journal: Ann Epidemiol Date: 2019-07-12 Impact factor: 3.797
Authors: Michael Fritz; Anna M Klawonn; Qingyu Zhao; Edith V Sullivan; Natalie M Zahr; Adolf Pfefferbaum Journal: J Neuroimmunol Date: 2020-08-26 Impact factor: 3.478
Authors: Aaron Samuel Breslow; Nathaniel M Tran; Frederick Q Lu; Jonathan E Alpert; Benjamin Lê Cook Journal: Curr Psychiatry Rep Date: 2019-09-21 Impact factor: 5.285